If standard treatments haven’t worked, don’t lose hope. Discover what treatment-resistant bipolar disorder means and new ...

The FDA has approved risperidone once-monthly, extended-release injectable suspension for maintenance treatment of bipolar I ...

Uzedy administered once every 2 months is not recommended for the maintenance treatment of bipolar I disorder. The Food and Drug Administration (FDA) has approved Uzedy ® (risperidone extended-release ...

The approval is supported by a combination of current clinical data and model-informed drug development techniques.

The Walsh Research Institute (WRI) announces a major scientific breakthrough in understanding bipolar disorder, revealed in The Essence of Bipolar Disorder by William J. Walsh, Ph.D. (Skyhorse ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best high volume stocks to buy according to Wall Street ...

Bipolar disorder treatment often includes some combination of medications like mood stabilizers and antidepressants alongside therapy.

On World Mental Health Day, this writer narrates her story of struggling with bipolar disorder, an illness that has ...

FDA approves UZEDY® (risperidone) extended-release injectable suspension for subcutaneous use as monotherapy or as adjunctive ...

Teva Pharmaceuticals' Uzedy therapy to treat bipolar I disorder received approval from the Food and Drug Administration. The biopharmaceutical company said Friday the therapy was approved as a ...

While borderline personality disorder and bipolar disorder share common symptoms like reckless behavior, there are a few key ...

The FDA expanded the approval of once-monthly risperidone (Uzedy) to include adjunct treatment for bipolar I disorder, ...